drugset / Trial / NCT03481946
A Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe Hemophilia
NaSingle-groupOpen-labelBasic science
Summary
The primary objective of this study is to assess the pharmacokinetics in patients with severe hemophilia. The secondary objective is to assess the pharmacodynamics of BAY1093884 based on tissue factor pathway inhibitor activity
Timeline
- Start
- 2018-05-10
- Primary completion
- 2018-10-17
- Completion
- 2019-02-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BAY1093884 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | BAY1093884 | Monoclonal antibody | 1 mg/kg | Intravenous |